ARIAD price target raised to $23 from $20 at RBC Capital RBC Capital increased its target on ARIAD as the firm believes that the potential opportunities of the company's '113 drug for ALK mutations will become clearer over the next 6-12 months. The firm maintains an Outperform rating on the stock.
Market Data 
Markets 
AI
